Einav Kadour Peero, Shorooq Banjar, Rabea Khoudja, Shaonie Ton-Leclerc, Coralie Beauchamp, Joanne Benoit, Marc Beltempo, Michael H Dahan, Phil Gold, Isaac Jacques Kadoch, Wael Jamal, Carl Laskin, Neal Mahutte, Simon Phillips, Camille Sylvestre, Shauna Reinblatt, Bruce D Mazer, William Buckett, Genevieve Genest
The effectiveness of intravenous immunoglobulin (IVIg) for patients with unexplained recurrent implantation failure (uRIF) remains debated. We retrospectively analysed outcomes of uRIF patients treated with IVIg compared to a separate control uRIF cohort within our center (01/2014-12/2021). Primary outcomes included live birth, miscarriage, or transfer failure. We documented IVIg side effects and maternal/fetal outcomes. Logistic regression analysis was used to assess for association of IVIg exposure with outcomes and adjust for confounders...
February 16, 2024: Scientific Reports